Bước đầu đánh giá biểu hiện của CD81 và mối liên quan với đáp ứng điều trị phác đồ tấn công ở bệnh nhân lơ xê mi cấp dòng tủy tại bệnh viện Bạch Mai=Initial assessment of CD81 expression and its relationship with initial treatment response in patients with acute myeloid leukemia at Bach Mai hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Vinh An Đỗ, Lan Anh Lê, Tuấn Tùng Nguyễn, Quang Vinh Phạm

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.517-523

Bộ sưu tập: Metadata

ID: 478318

Thêm vào giỏ

Mô tả mức độ biểu hiện CD81 ở bệnh nhân lơ xê mi (LXM) cấp dòng tủy và mối liên quan của nó với đáp ứng điều trị bằng phác đồ tấn công. Đối tượng và phương pháp: Mô tả loạt ca bệnh trên 110 bệnh nhân LXM cấp dòng tủy được chẩn đoán mới tại Trung tâm Huyết học - Truyền máu Bệnh viện Bạch Mai từ tháng 6/2021 đến 6/2023. Bệnh nhân được phân tích dấu ấn miễn dịch CD81 bằng xét nghiệm flow cytometry tại thời điểm mới chẩn đoán, sau đó bệnh nhân được điều trị phác đồ tấn công, đánh giá kết quả điều trị sau 28 ngày. Kết quả: Đa số bệnh nhân có tuổi trên 50 với 59,1%, tuổi trung bình là 50,1, thấp nhất 17 tuổi, cao nhất 83 tuổi, nam nhiều hơn nữ (57,3% so với 42,7%). Thể lâm sàng chủ yếu là M4 với 30,9%. Bệnh nhân đa số có CD81 dương tính với 61,8% với giá trị trung bình là 30,4%. Tỉ lệ lui bệnh hoàn toàn ở nhóm CD81- cao nhất với 74,2%, thấp nhất là nhóm CD81++ 25,0%. Tỉ lệ tử vong trong giai đoạn cảm ứng cao nhất ở nhóm CD81++ (41,7%). Kết luận: CD81 có mức độ biểu hiện cao ở bệnh nhân LXM cấp dòng tủy, và có mối liên quan đến đáp ứng điều trị của bệnh nhân.To investigate CD81 expression level in acute myeloid leukemia (AML) patients and its association with initial treatment response. Populations and Methods: A case series report on 110 AML patients newly diagnosed at the Hematology and Transfusion Center of Bach Mai Hospital from June 2021 to June 2023. At the time of diagnosis, the CD81 expression level was analyzed by flow cytometry. The patient was treated with an attack regimen, treatment results were evaluated after 28 days. Results: The majority of patients were over 50 years old, with 59.1%, the average age was 50.1 years old
the lowest was 17 years old, the highest was 83 years old, and there were more men than women (57.3% compared to 42.7%). The main clinical form was M4, with 30,9%. Most patients had CD81 positive with 61.8%
the average value was 30.4%. The complete remission rate in the CD81- group was highest at 74.2%, followed by the CD81+ group with 31.4% and the CD81++ group with 25.0%. The mortality rate during the induction period was highest in the CD81++ group with 34.8%. Conclusion: CD81 high expression in AML patients was associated with initial treatment response.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR